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Purpose or Objective
To determine the evolution of Quality of Life (QoL) within
the 1st year after RT for prostate cancer (PC) and its
relationship with RT-related urinary and bowel symptoms
(symp).
Material and Methods
Patients (pts) in a multicenter observational study aimed
at evaluation of symp and QoL after WPRT were included.
Bowel toxicity was scored by means of the Inflammatory
Bowel Disease Questionnaire (IBDQ), including QoL scales
evaluating both social (SWB) and emotional (EWB)
wellbeing. In IBDQ scales (range 1-7) lower scores indicate
worse outcome. Moreover, QoL was also measured through
the Hospital Anxiety and Depression Scale (HADS), which
scores anxiety (ANX) and depression (DEP) separately
(range 0-21 for both, greater values mean increased
severity, score ≥8 indicating ANX/DEP mood). Urinary
toxicity was scored through both the IPSS (range 0-35)
(range 0-21), with greater scores indicating increased
symptom’s severity for both questionnaires.
Longitudinal evaluation of QoL in the 1st year after RT was
analyzed by means of ANOVA for multiple measures.
Associations between urinary/bowel symp and
1.worsening of SWB/EWB of at least 2 points compared to
baseline and 2.presence of ANX/DEP mood at 1 year were
evaluated by means of logistic regression (LR).
Results
304 pts were available for longitudinal evaluation, 38%
treated with conventional RT and 62% with moderate
hypofractionation with radical (28%), adjuvant (33%) or
salvage (39%) intent. Median EQD2Gy (a/b=3Gy) to
prostate/prostatic bed was 74Gy, that to pelvic nodes
50Gy.
Evolution of QoL over time was characterized by a
quadratic trend for SWB & EWB (p>0.001), with significant
worsening at RT end and subsequent recovery after RT
completion. Conversely, ANX & DEP could be described by
a linear decreasing trend (p=0.002/p=0.01), reaching the
lowest average values at 1 yr (see Figures 1 and 2).
At multivariate LR, SWB worsening (23 pts) was associated
to urinary obstructive symp (OR=1.09 for 1-point IPSS 
increase, p=0.006), while EWB worsening (9 pts) was
associated to bowel symp (OR=5 for 1-point IBDQ
decrease, p=0.001) .
ANX mood (30 pts) was independently associated with both
urinary obstructive symp (OR=1.12 for 1-point IPSS 
increase, p=0.001) and bowel symp (OR=3.2 for 1-point
IBDQ decrease, p=0.0007). DEP mood (18 pts) was
associated to urinary incontinence (OR=1.14 for 1-point
ICIQ increase, p=0.001).
ANX/DEP at 1 year were highly negatively correlated with
EWB (r=-0.79/-0.71, p<0.001).
Conclusion
SWB & EWB after WPRT for PC are both decreased shortly
after RT completion but recover within 1 year, with a
limited number of pts reporting worsening SWB/EWB
scores at 1 year, mainly associated with persistent bowel
and obstructive urinary symp.
ANX/DEP decrease over time, suggesting their being more
related to emotional upset following PC diagnosis rather
than to treatment and side effects. Residual presence of
ANX/DEP mood is significantly associated to both bowel
and urinary symp.
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Purpose or Objective
External beam radiation therapy plus brachytherapy boost
is a highly effective treatment for unfavorable prostate
cancer. However, utilization of brachytherapy in the
United States is declining and not all patients are ideal
candidates for this treatment approach due to technical
reasons. Stereotactic body radiotherapy (SBRT) has
emerged as a standard high dose option for low and
favorable intermediate risk prostate cancer patients. In
this report, we present the biochemical disease free
survival for unfavorable prostate cancer treated with SBRT
in a large single institution cohort.
Material and Methods
All patients with unfavorable intermediate risk (more than
one intermediate risk factor, GS 4+3, or greater than 50%
positive biopsy cores) and high risk prostate cancer
treated with SBRT at a single institution were eligible for
this study. Treatment was delivered using the robotic
SBRT with doses of 35-36.25 Gy in five fractions or 19.5 Gy
in three fractions followed by fiducial-guided
supplemental IMRT (45–50.4 Gy). In general, patients with
high grade, non-organ confined disease received
supplemental IMRT. Patient’s characteristics were
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Purpose or Objective 
To apply a voxel-based analysis on the planning 3D dose 
distribution in order to identify symptom-related 
subregions (SRSs) of the bladder/urethra associated with 
acute and late urinary toxicity in prostate cancer radiation 
therapy (RT). 
Material and Methods 
Overall, 272 prostate cancer patients treated with 
IMRT/IGRT from two multicentric prospective phase III 
trials were analyzed. Each patient’s organ contours 
(bladder, urethra and prostate) were spatially normalized 
to a common coordinate system (CCS) via non-rigid 
registration. The obtained 3D deformation fields were 
used to propagate the planning dose distributions from the 
native space of each patient to the CCS. A voxel-based 
statistical analysis was applied to generate 3D dose-
volume maps for different urinary symptoms and identify 
corresponding SRSs with statistically significant dose 
differences between patients with/without toxicity. All 
the identified SRSs were propagated from the CCS back to 
the native space of each individual and DVHs for the SRSs 
and the whole bladder were computed. Dose bins of 
significant dose difference between patients with/without 
urinary toxicity were identified. Logistic regression was 
used to estimate the DVH  prediction capability (1Gy bin-
wise) of the SRSs compared to the whole bladder. 
Results 
A local dose-effect relationship was found in the bladder 
and the urethra. SRSs of significant dose differences (p-
value<0.01) were identified for four endpoints: acute and 
late incontinence in the urethra and the trigone, late 
retention and dysuria in the posterior part of the bladder, 
with average dose differences ranging from 1.26 to 9.28 
Gy. Figure 2 shows these SRSs onthe template. The DVHs 
of the SRSs were significantly predictive of toxicity with 
maximum areas under the ROC curve (AUC): 71% for acute 
incontinence, 80% for late incontinence, 68% for late 
retention and 79% for late dysuria. The DVH of the bladder 
was predictive only for late incontinence and late dysuria 
(AUC=70%). Table 1 shows the prediction capability of the 
DVH for the SRSs and the whole bladder in the native 
space. 
Conclusion 
The dose delivered to the urethra, the trigone and the 
posterior region of the bladder was predictive of acute and 
late incontinence, late retention and late dysuria. These 
SRSs appear more predictive than the whole bladder, 
suggesting that identification of radiosensitive subregions 
can improve the prediction capabilities for urinary toxicity 
and may be spared in order to decrease urinary symptoms. 
Additionally, this study provides the first evidence that 
explicitly correlate the true 3D dose to the urethra with 
urinary toxicity following EBRT.  
